ASCO: Triple therapy regimen significantly improves survival in BRAF V600E-mutated metastatic colorectal cancer
Approximately 8 to 12% of patients with colorectal cancer have BRAF mutations
Treatment with the triplet combination of drugs – encorafenib, cetuximab and chemotherapy – helped patients live longer and kept cancer from progressingÂ
The Food and Drug Administration granted accelerated approval for this new combination in Dec. 2024Â
Median overall survival was 30.3 months with the triplet therapy, compared to 15.1 months with standard...
Combination of dual-targeted therapies and chemotherapy shows high response rates in BRAF-mutated metastatic colorectal cancer
ABSTRACT: 16
Patients with metastatic colorectal cancer (mCRC) harboring BRAF V600E mutations benefitted from first-line treatment...
Combining targeted therapy and immunotherapy improves overall survival in patients with anaplastic thyroid cancer
Researchers from Â鶹ӳ» MD Anderson Cancer Center demonstrated that anti-PD-L1 immunotherapy in combination with mutation-directed targeted therapy extended overall survival (OS) in patients with anaplastic thyroid carcinoma (ATC). Findings from the Phase II single center study published today in JAMA Oncology.
The trial enrolled 42 patients across three cohorts to evaluate mutation-matched targeted therapy and...
